Grufity logoGrufity logo
StocksFundsScreenerSectorsWatchlists
NUVL

NUVL - Nuvalent, Inc. Stock Price, Fair Value and News

$123.23-0.22 (-0.18%)
Market Closed as of 12 Jun 2026, 04:00 pm ET

15/100

NUVL

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

15/100

NUVL

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

NUVL Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

NUVL Price Action

Last 7 days

35.5%

Last 30 days

17.1%

Last 90 days

25.8%

Trailing 12 Months

58.2%

NUVL RSI Chart

NUVL Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

NUVL Valuation

Market Cap

9.7B

Price/Earnings (Trailing)

-21.54

Price/Sales (Trailing)

211.75

EV/EBITDA

-21.21

Price/Free Cashflow

-30.99

NUVL Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

NUVL Fundamentals

NUVL Revenue

Revenue (TTM)

45.8M

Rev. Growth (Yr)

8.88%

Rev. Growth (Qtr)

10.78%

NUVL Earnings

Earnings (TTM)

-450.1M

Earnings Growth (Yr)

-29.22%

Earnings Growth (Qtr)

7.92%

NUVL Profitability

EBT Margin

-981.74%

Return on Equity

-38.33%

Return on Assets

-33.81%

Free Cashflow Yield

-3.23%

NUVL Investor Care

Shares Dilution (1Y)

9.86%

Diluted EPS (TTM)

-6.06

NUVL Alerts

  • 4 major insider sales recently.
  • Losses in recent quarter

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202645.8M000
202541.6M44.6M46.2M44.7M
202426.7M29.9M33.4M38.3M
20239.1M13.8M18.3M23.3M
20221.1M2.2M3.2M4.3M
2021000114.0K
Get all data in R, Python etc through our Historical Stock Data APIs

About Nuvalent, Inc.

NUVL
Nuvalent, Inc., a clinical stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferring resistance to approved and investigational ROS1 inhibitors, which is under Phase I development; NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, central nervous system-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under Phase ½ clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20, brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR, which is ongoing IND-enabling studies. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.
 CEO
 WEBSITEnuvalent.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES78

Nuvalent, Inc. Frequently Asked Questions

NUVL is the stock ticker symbol of Nuvalent, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

As of Fri Jun 12 2026, market cap of Nuvalent, Inc. is 9.69 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

As of Fri Jun 12 2026, NUVL's PE ratio (Price to Earnings) is -21.54 and Price to Sales (PS) ratio is 211.75. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. NUVL PE ratio will change depending on the future growth rate expectations of investors.